Pfizer: CDC committee recommends new dosing schedule for TRUMENBA vaccination
Pfizer announced that the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices, or ACIP, voted to recommend that: for persons at increased risk for meningococcal disease and for use during serogroup B outbreaks, 3 doses of TRUMENBA should be administered at 0, 1-2, and 6 months; when given to healthy adolescents who are not at increased risk for meningococcal disease, 2 doses of TRUMENBA should be administered at 0 and 6 months. "Today's ACIP recommendation is an important update that offers clear guidance to healthcare providers administering TRUMENBA to help prevent meningococcal group B disease, also known as MenB, in healthy adolescents and young adults, as well as those at increased risk for the disease," said Dr. Laura York, Global Medical Lead for Meningococcal Vaccines, Pfizer Vaccines. "This new recommendation enables flexible vaccination dosing intervals depending on one's risk of exposure to MenB, which makes it easier for healthcare providers to help protect individuals from this uncommon but life-threatening disease." The ACIP recommendation will be forwarded to the director of the CDC and the U.S. Department of Health and Human Services for review and approval. Once approved, the recommendations are published in the Morbidity and Mortality Weekly Report.